DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1004918
Title:
A Partnership Training Program: Studying Targeted Drug Delivery Using Nanoparticles In Breast Cancer Diagnosis and Therapy
Descriptive Note:
Technical Report,15 Sep 2010,14 Sep 2015
Corporate Author:
Howard University Washington United States
Report Date:
2015-12-01
Pagination or Media Count:
136.0
Abstract:
Howard University HU Imaging Core has fully accomplished the goals of this training program. For five years, the Core was able to establish a Nanomedicine Core Lab that served as a ground for learning, training and professional development to 14 faculty, 14 non-HU scientists, 14 postdoctoral fellows, 21 graduate 2 of whom received Ph.D. degree and 7 undergraduate students. Faculty trainees and postdocs of the program have submitted grants to various agencies and seminars, webinars, workshops and symposia in cancer, molecular imaging and nanomedicine. The Nanomedicine Core became a synergy center drawing some received funding and invitation to submit a full proposal. The Core received various grants to not only further support the Univermultidisciplinary research collaborations using nanotechnology for targeted drug delivery and improving breast cancer diagnosis and therapy. Various peer-reviewed publications and presentations resulted from this training grant. The two research projects were successfully completed. Liposomes were generated with a narrow size distribution. A novel recombinant immunotoxin DT390-BiscFv806 that is highly promising for treatment of cancers arising from the brain, head and neck, lung, breast, and prostate were generated. Aside from these two research projects, several additional projects using computer modeling to study docking process between nanoparticles and their intended targets in cancer cells, using a convex analysis of mixtures algorithm to study compartmental modeling of MRI-DCE pattern of targeted delivery of nanoparticle containing MR contrast agent and the liposome use as drug delivery vehicle for cancer diagnosis.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
